On Stockhead today, Our Josh Chiat corners Coda Minerals boss Chris Stevens for a quick chat about the improper price of copper.

Reuben Adams tracks down the pastors in Zimbabwe helping perpetrating the world’s best gold smuggling racquet.

Finally, it looks like we might have a bit of a problem with US (commercial) mortgage-backed securities. Me and James Whelan think you should probably take a moment to check it out.

But first, the day ahead.



The following stocks went into trading halts Friday and are expected out in the coming days:

Globe Metals & Mining (ASX:GBE) – Signing of the Mining Development Agreement for the Company’s Kanyika Niobium Project.

Chalice Mining (ASX:CHN) – Mineral resource estimate update.

Kingsgate Consolidated (ASX:KCN) – Capital raising.

United Malt Group (ASX:UMG) – Potential change of control transaction.

Walkabout Resources (ASX:WKT) – Execution of a senior debt financing facility. Brutal, but they probably had it coming.



Gold: $US1,978.57 (-0.75%)

Silver: $US23.21 (+0.41%)

Nickel (3mth): $US23,268/t (+4.50%)

Copper (3mth): $US8518.50/t (+0.16%)

Oil (WTI): $US69.26 (-1.00%)

Oil (Brent): $US74.99 (-1.21%)

Iron 62pc Fe: $US126.00/t (-0.51%)

AUD/USD: 0.6645 (-0.58%)

Bitcoin: $US27,749 (+0.99%)



Big developments in the lithium game did.

For all you crypto lovers Stockhead’s Coinhead Facebook group is the place to share your views, insights, tips and ideas.

Also, be sure to check in preopen each day for ‘Market highlights and 5 ASX small caps to watch’, and 10.30am for our daily ‘10 at 10’ column — a live summary of winners & losers at the opening bell.



Here are the best performing ASX small cap stocks:

Swipe or scroll to reveal full table. Click headings to sort:

Wordpress Table Plugin


Impedimed (ASX:IPD), surged 120% on news that the US National Comprehensive Cancer Network (NCCN) released a new set of guidelines, which include the use of bioimpedance spectroscopy as an objective measurement tool to identify early signs of lymphoedema for the first time.

That’s very big news for the company which currently holds the only FDA-cleared BIS technology for the assessment of lymphoedema.

Alloggio Group (ASX:ALO), announced  a Scheme Implementation Deed (SID) with Next Capital, which would see the latter acquire 100% of ALO shares at $0.30 a pop. ALO is still 45% higher at $0.275 per share.

Godolphin Resources (ASX:GRL) added 34% on no fresh news, but continuing it’s climb since announcing solid copper finds at its Cyclops and Goodrich projects earlier this month.

Proteomics International Laboratories (ASX:PIQ) found more than 15% after showing off its latest tech in the hunt for a treatment for endometriosis.



Here are the worst performing ASX small cap stocks:

Swipe or scroll to reveal full table. Click headings to sort:

Wordpress Table Plugin